Literature DB >> 17592730

Prepared and screened a modified TNF-alpha molecule as TNF-alpha autovaccine to treat LPS induced endotoxic shock and TNF-alpha induced cachexia in mouse.

Yi Wan1, Xiaochang Xue, Meng Li, Xiaoyong Zhang, Xin Qin, Cun Zhang, Yanjie You, Weihua Wang, Changli Jiang, Shouzhen Wu, Yan Liu, Wenhua Zhu, Yonggang Ran, Zhen Zhang, Wei Han, Yingqi Zhang.   

Abstract

Overexpression of TNF-alpha in the body is critically involved in many diseases. A strategy to construct TNF-alpha autovaccine by introducing a T cell helper epitope to the protein has been developed and may be an alternative because it is cheaper and highly efficient. However, the induction of high level anti-TNF-alpha neutralizing autoantibodies by TNF-alpha autovaccine is depend on a proper T cell help epitope. In order to evaluate the effect of different T helper cell epitopes on the immunogenicity of mouse TNF-alpha (mTNF-alpha), three T helper cell epitopes, TT (QYIKANSKFIGITEL), HEL (NTDGSTDYGILQINSR), and PADRE (AKFVAAWTLKA), were chosen for this study. The sequence (amino acids 126-140) of mTNF-alpha was replaced with those of the T cell help epitopes, respectively. The three fusion proteins (mTNF-TT, mTNF-HEL, mTNF-PADRE) were expressed in Escherichia coli and purified with a simple strategy. The abilities of the proteins elicited TNF-alpha autoantibodies in BALB/c mice were investigated. The results showed that mTNF-PADRE is the most effective among the three modified TNF-alpha molecules. In the absence of adjuvant, the therapeutic effect of TNF-PADRE on LPS induced endotoxic shock mice and mTNF-alpha induced cachexia mice was observed. This study suggests that mTNF-PADRE may be a better candidate of mTNF-alpha autovaccine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17592730     DOI: 10.1016/j.cellimm.2007.05.005

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  5 in total

1.  Staphylococcus aureus infection after splenectomy and splenic autotransplantation in BALB/c mice.

Authors:  F M Teixeira; B F Fernandes; A B Rezende; R R P Machado; C C S Alves; S M Perobelli; S I Nunes; R E Farias; M F Rodrigues; A P Ferreira; S C Oliveira; H C Teixeira
Journal:  Clin Exp Immunol       Date:  2008-09-08       Impact factor: 4.330

2.  Active immunotherapy for TNF-mediated inflammation using self-assembled peptide nanofibers.

Authors:  Carolina Mora-Solano; Yi Wen; Huifang Han; Jianjun Chen; Anita S Chong; Michelle L Miller; Rebecca R Pompano; Joel H Collier
Journal:  Biomaterials       Date:  2017-09-26       Impact factor: 12.479

3.  Attenuating effect of pretreatment with Yiqifumai on lipopolysaccharide-induced intestine injury and survival rate in rat.

Authors:  Qing Yuan; Jing Wang; Qiu-Hong Fang; Yu-Ying Liu; Jing-Yu Fan; Shu-Wen Zhang; Ying-Min Ma
Journal:  J Inflamm (Lond)       Date:  2011-05-02       Impact factor: 4.981

4.  Production of Human Cu,Zn SOD with Higher Activity and Lower Toxicity in E. coli via Mutation of Free Cysteine Residues.

Authors:  Kun Zhang; Yuejuan Zhang; Jing Zi; Xiaochang Xue; Yi Wan
Journal:  Biomed Res Int       Date:  2017-02-16       Impact factor: 3.411

5.  A Single Codon Optimization Enhances Recombinant Human TNF-α Vaccine Expression in Escherichia coli.

Authors:  Chu Chu; Wangqian Zhang; Jialin Li; Yi Wan; Zenglu Wang; Ruyi Duan; Pei Yu; Ning Zhao; Kuo Zhang; Shuning Wang; Qiang Hao; Weina Li; Cun Zhang; Wei Zhang; Yingqi Zhang; Meng Li; Xiaochang Xue
Journal:  Biomed Res Int       Date:  2018-04-15       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.